Effectiveness of electroacupuncture versus prucalopride for women with severe chronic constipation : secondary analysis of a randomized controlled trial
© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature..
PURPOSE: Electroacupuncture (EA) is a component alternative therapy for severe chronic constipation (SCC). Women are more vulnerable to SCC and gender might impact the response of patients with functional gastrointestinal disorders to therapy. We performed this secondary analysis to explore the effectiveness and safety of EA compared with prucalopride among women with SCC.
METHODS: Based on a multicenter, randomized, noninferiority trial, 446 female patients were randomly assigned to receive 28-session EA (n = 222) over 8 weeks with 24-week follow-up without treatment or to receive prucalopride (n = 224) over 32 consecutive weeks. The primary outcome was the proportion of overall complete spontaneous bowel movements (CSBMs) responders over weeks 1-8, defined as at least three CSBMs per week, and more than an increase of one CSBM from baseline meanwhile for at least 6 weeks during an 8-week treatment period. Secondary outcomes measure sustained CSBM responder, weekly responders, change from baseline in mean weekly CSBMs and SBMs, straining and stool consistency, quality of life, and adverse events (AEs).
RESULTS: The proportion of overall responders was 25.23% in the EA group, similar to 25.89% in the prucalopride group, with a between-group difference of - 0.67% (95% CI, - 8.80 to 7.40%; P = 0.872) during an 8-week treatment. In the secondary outcomes, EA and prucalopride groups had no significant difference, except that EA was inferior to prucalopride in improving SBMs. The AEs were less in the EA group than the prucalopride group.
CONCLUSION: EA may be a promising and safe treatment for women with SCC; its effect could sustain 24 weeks after treatment stopped.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:38 |
|---|---|
| Enthalten in: |
International journal of colorectal disease - 38(2023), 1 vom: 20. Jan., Seite 20 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Wang, Xinlu [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
0A09IUW5TP |
|---|
| Anmerkungen: |
Date Completed 24.01.2023 Date Revised 21.12.2023 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s00384-023-04313-z |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM351730427 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM351730427 | ||
| 003 | DE-627 | ||
| 005 | 20231227135150.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s00384-023-04313-z |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1234.xml |
| 035 | |a (DE-627)NLM351730427 | ||
| 035 | |a (NLM)36662303 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Wang, Xinlu |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Effectiveness of electroacupuncture versus prucalopride for women with severe chronic constipation |b secondary analysis of a randomized controlled trial |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 24.01.2023 | ||
| 500 | |a Date Revised 21.12.2023 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature. | ||
| 520 | |a PURPOSE: Electroacupuncture (EA) is a component alternative therapy for severe chronic constipation (SCC). Women are more vulnerable to SCC and gender might impact the response of patients with functional gastrointestinal disorders to therapy. We performed this secondary analysis to explore the effectiveness and safety of EA compared with prucalopride among women with SCC | ||
| 520 | |a METHODS: Based on a multicenter, randomized, noninferiority trial, 446 female patients were randomly assigned to receive 28-session EA (n = 222) over 8 weeks with 24-week follow-up without treatment or to receive prucalopride (n = 224) over 32 consecutive weeks. The primary outcome was the proportion of overall complete spontaneous bowel movements (CSBMs) responders over weeks 1-8, defined as at least three CSBMs per week, and more than an increase of one CSBM from baseline meanwhile for at least 6 weeks during an 8-week treatment period. Secondary outcomes measure sustained CSBM responder, weekly responders, change from baseline in mean weekly CSBMs and SBMs, straining and stool consistency, quality of life, and adverse events (AEs) | ||
| 520 | |a RESULTS: The proportion of overall responders was 25.23% in the EA group, similar to 25.89% in the prucalopride group, with a between-group difference of - 0.67% (95% CI, - 8.80 to 7.40%; P = 0.872) during an 8-week treatment. In the secondary outcomes, EA and prucalopride groups had no significant difference, except that EA was inferior to prucalopride in improving SBMs. The AEs were less in the EA group than the prucalopride group | ||
| 520 | |a CONCLUSION: EA may be a promising and safe treatment for women with SCC; its effect could sustain 24 weeks after treatment stopped | ||
| 650 | 4 | |a Randomized Controlled Trial | |
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Acupuncture | |
| 650 | 4 | |a Female | |
| 650 | 4 | |a Functional bowel dysfunction | |
| 650 | 4 | |a Post hoc analysis | |
| 650 | 7 | |a prucalopride |2 NLM | |
| 650 | 7 | |a 0A09IUW5TP |2 NLM | |
| 700 | 1 | |a Sun, Yuanjie |e verfasserin |4 aut | |
| 700 | 1 | |a Yan, Shiyan |e verfasserin |4 aut | |
| 700 | 1 | |a Shi, Hangyu |e verfasserin |4 aut | |
| 700 | 1 | |a Zhu, Lili |e verfasserin |4 aut | |
| 700 | 1 | |a Gao, Shuai |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Zhishun |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t International journal of colorectal disease |d 1996 |g 38(2023), 1 vom: 20. Jan., Seite 20 |w (DE-627)NLM012646059 |x 1432-1262 |7 nnns |
| 773 | 1 | 8 | |g volume:38 |g year:2023 |g number:1 |g day:20 |g month:01 |g pages:20 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s00384-023-04313-z |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 38 |j 2023 |e 1 |b 20 |c 01 |h 20 | ||